RBOT

8-K - Vicarious Surgical Inc. (0001812173) (Filer)

SCHEDULE 13D/A - Vicarious Surgical Inc. (0001812173) (Subject)

WALTHAM, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB:RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the "Company"), today announced the successful completion of initial integrated benchtop testing for its full suite of surgical instruments, required for its anticipated first clinical indication of ventral hernia repair, marking an important step toward design validation, clinical readiness, and the Company's targeted design freeze milestone. This milestone represents the first system-level performance evaluation of the Company's three core instruments: needle drivers, fenestrated graspers, and monopolar sc

WALTHAM, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB:RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the "Company"), today announced that it has received approval for its Class A common stock to upgrade to the OTCQB® Venture Market by OTC Markets Group Inc. (the "OTCQB"). The Company's Class A common stock has begun quotation on the OTCQB as of March 24, 2026, under the ticker symbol RBOT. This milestone represents a key step in the Company's broader capital markets strategy as it advances toward a potential listing on the Nasdaq Capital Market. The OTCQB is designed for early-stage and developing companies

DEF 14A - Vicarious Surgical Inc. (0001812173) (Filer)

25-NSE - Vicarious Surgical Inc. (0001812173) (Subject)

PRE 14A - Vicarious Surgical Inc. (0001812173) (Filer)

8-K - Vicarious Surgical Inc. (0001812173) (Filer)

10-K - Vicarious Surgical Inc. (0001812173) (Filer)

8-K - Vicarious Surgical Inc. (0001812173) (Filer)

8-K - Vicarious Surgical Inc. (0001812173) (Filer)

Vicarious Surgical Inc. (NYSE:RBOT) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that on March 3, 2026, it received a notice (the "Notice") from the New York Stock Exchange (the "NYSE") that the NYSE has commenced the process of delisting the Company's Class A common stock, par value $0.0001 per share (the "Common Stock"). Trading on the Company's Common Stock on the NYSE was suspended after market close on March 3, 2026. The NYSE has determined that the Company has fallen below the continued listing standard, requiring listed companies to maintain an average global market capitalization over a con

4 - Vicarious Surgical Inc. (0001812173) (Issuer)

4 - Vicarious Surgical Inc. (0001812173) (Issuer)

8-K - Vicarious Surgical Inc. (0001812173) (Filer)

Vicarious Surgical (NYSE:RBOT) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the successful completion of an in-vivo porcine lab conducted in December 2025, marking a meaningful step forward in the development of the company's robotic system and reinforcing progress toward system design freeze targeted for the end of 2026. During the lab, surgeons independently completed key elements of a ventral hernia repair using Vicarious Surgical's pre-DV system as part of a limited-scope feasibility assessment. In parallel, the company executed a series of targeted technical evaluations designed to assess syst

8-K - Vicarious Surgical Inc. (0001812173) (Filer)

Vicarious Surgical Inc. (NYSE:RBOT) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that it has entered into a strategic partnership agreement with a global digital engineering and software development services firm. This engagement is a central component of the Company's broader operating model transformation, designed to improve execution, increase development predictability, and reduce operating expenses as reflected in the Company's cash burn guidance, through a more efficient mix of internal and external engineering resources. Under the agreement, the external engineering partner will assume resp

EFFECT - Vicarious Surgical Inc. (0001812173) (Filer)

424B5 - Vicarious Surgical Inc. (0001812173) (Filer)

25-NSE - Vicarious Surgical Inc. (0001812173) (Subject)

8-K - Vicarious Surgical Inc. (0001812173) (Filer)

Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced its full-year 2026 cash burn guidance. Vicarious Surgical expects full-year 2026 cash burn of approximately $35 million, representing a $10 million improvement from the Company's recently updated 2025 guidance of $45 million. Cash needs beyond existing cash resources to achieve design freeze on the Vicarious Surgical system are approximately $25 million. The improved guidance reflects a strong continuation of the Company's operational reset. Key drivers include reductions in headcount and external consulting s

S-3 - Vicarious Surgical Inc. (0001812173) (Filer)

424B3 - Vicarious Surgical Inc. (0001812173) (Filer)